S-72, a Novel Orally Available Tubulin Inhibitor, Overcomes Paclitaxel Resistance via Inactivation of the STING Pathway in Breast Cancer

S-72, a Novel Orally Available Tubulin Inhibitor, Overcomes Paclitaxel Resistance via Inactivation of the STING Pathway in Breast Cancer

Microtubule-targeting agents are widely used as active anticancer drugs. However, drug resistance always emerges after their long-term use, especially in the case of paclitaxel, which is the cornerstone of all subtypes of breast cancer treatment. Hence, the development of novel agents to overcome th...

Full description

Bibliographic Details
Main Authors: Zhenyan Hou, Songwen Lin, Tingting Du, Mingjin Wang, Weida Wang, Shen You, Nina Xue, Yichen Liu, Ming Ji, Heng Xu, Xiaoguang Chen
Format: Article
Language:English
Published: MDPI AG 2023-05-01
Series:Pharmaceuticals
Subjects:
microtubule-destabilizing agent
breast cancer
paclitaxel resistance
STING
chromosomal instability
Online Access:https://www.mdpi.com/1424-8247/16/5/749

Internet

https://www.mdpi.com/1424-8247/16/5/749

Similar Items